General advice only. SureStone Capital Pty Ltd (ABN 92 681 118 212) is a Corporate Authorised Representative (No. 1314938) of River X Financial Services Pty Ltd (AFSL 556458).
Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.
All Telix Pharmaceuticals Limited (ASX:TLX) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.
Telix reported Q3 2026 group revenue of US$245 million, up 19%, reaffirmed FY 2026 revenue and other income above US$1 billion and revised its R&D guidance.
21 Oct, 2026
Telix receives FDA Fast Track for BiPASS pre-biopsy PSMA-PET with MRI, after completing Phase 3 enrollment for its Illuccix and Gozellix imaging agents.
30 Sep, 2026Telix will lead a merger with ITM for US$1.65bn upfront cash-free/debt-free, plus up to US$700m contingent on ITM-11 milestones, subject to approvals.
21 Sep, 2026The FDA has approved Telix's Pixclara (18F-FET) NDA, the first FDA-approved FET-PET imaging drug for glioma in adults and pediatric patients from 1 month.
14 Sep, 2026